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The renin-angiotensin system (RAS) is associated with peripheral ﬂuid homeostasis and cardiovascular
function, but recent evidence also suggests a functional role in the brain. RAS regulates physiological and
behavioral parameters related to the stress response, including depressive symptoms. Apparently, RAS
can modulate levels of brain-derived neurotrophic factor (BDNF) and TRKB, which are important in the
neurobiology of depression and antidepressant action. However, the interaction between the BDNF/TRKB
system and RAS in depression has not been investigated before. Accordingly, in the forced swimming
test, we observed an antidepressant-like effect of systemic losartan but not with captopril or enalapril
treatment. Moreover, infusion of losartan into the ventral hippocampus (vHC) and prelimbic prefrontal
cortex (PL) mimicked the consequences of systemically injected losartan, whereas K252a (a blocker of
TRK) infused into these brain areas impaired such effect. PD123319, an antagonist of AT2 receptor
(AGTR2), also prevented the systemic losartan effect when infused into PL but not into vHC. Cultured
cortical cells of rat embryos revealed that angiotensin II (ANG2), possibly through AGTR2, increased the
surface levels of TRKB and its coupling to FYN, a SRC family kinase. Higher Agtr2 levels in cortical cells
were reduced after stimulation with glutamate, and only under this condition an interaction between
losartan and ANG2 was achieved. TRKB/AGTR2 heterodimers were also observed, in MG87 cells GFP-
tagged AGTR2 co-immunoprecipitated with TRKB. Therefore, the antidepressant-like effect of losartan
is proposed to occur through a shift of ANG2 towards AGTR2, followed by coupling of TRK/FYN and
putative TRKB transactivation. Thus, the blockade of AGTR1 has therapeutic potential as a novel anti-
depressant therapy.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The functional role of the renin-angiotensin system (RAS) has
historically been implicated in cardiovascular and ﬂuid homeosta-
sis. The precursor molecule angiotensinogen is cleaved by renin
into angiotensin I, which is then converted into angiotensin II
(ANG2) by angiotensin-converting enzyme (ACE) (Wright andersity of Helsinki, Haartma-
d.
.A.F. Diniz), plinio@gmx.com
, caroline.biojone@helsinki.ﬁ
ia@usp.br (S.R.L. Joca).
ier Ltd. This is an open access articHarding, 2011). The primary actions of ANG2 are mediated by
angiotensin II receptors type 1 (AGTR1) and 2 (AGTR2) (Wright and
Harding, 2011).
Other reports, however, have indicated that all components of
RAS are produced within the central nervous system (CNS)
(Saavedra, 2005). Thus, AGTR1 and AGTR2 in circumventricular
organs and in cerebrovascular endothelial cells may respond to
circulating ANG2 of peripheral origin, whereas neural receptors
inside the blood brain barrier respond to RAS of brain origin
(Saavedra, 2005). AGTR1 and AGTR2 are expressed inside blood
brain barrier structures such as the hippocampus and frontal cortex
(Bunnemann et al., 1992; Tsutsumi and Saavedra, 1991), which are
both considered crucial limbic structures associated with the
neurobiology of depression (Krishnan and Nestler, 2008).le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mone regulator of peripheral and central physiological changes
regarding stress exposure, including behavioral consequences. For
instance, both acute and chronic stress increased ANG2 and AGTR1
expression levels in the hypothalamic-pituitary-adrenal axis (HPA
axis) (Castren and Saavedra, 1988; Saavedra et al., 2004; Yang et al.,
1993). Moreover, candesartan (an AGTR1 antagonist) treatment
prevented the stress effect of increasing pituitary adrenocortico-
tropic and corticosterone hormone levels (Armando, 2001), and
treatment with ACE inhibitors (ACEi) or AGTR1 antagonists
reversed or prevented animal behavioral responses to stress (Gard
et al., 1999; Giardina and Ebert, 1989; Martin et al., 1990a, 1990b;
Ping et al., 2014; Vijayapandi and Nagappa, 2005). Similarly, ani-
mals lacking angiotensinogen showed an antidepressant-like
phenotype (Okuyama et al., 1999).
The neurotrophin brain-derived neurotrophic factor (BDNF) is
found mostly in the central nervous system and is important for
neural plasticity, including synapse formation, neuronal differen-
tiation, and growth (Park and Poo, 2013). The functional role of
BDNF and its receptor (tropomyosin-related kinase B receptor,
TRKB) has been linked to the pathophysiology of psychiatric dis-
orders (such as depression) and with the mechanism of action of
antidepressant drugs (Castren, 2014). RAS may modulate BDNF and
TRKB brain levels. For instance, candesartan treatment prevented
both infarct volume and neurological deﬁcits in animals submitted
tomiddle cerebral artery occlusion, and increased TRKB protein and
mRNA levels in the brain (Krikov et al., 2008). In addition, telmi-
sartan (an AGTR1 antagonist) chronic treatment prevented retinal
damage and decrease of BDNF levels in a diabetic animal model
(Ola et al., 2013). Valsartan, another AGTR1 antagonist, counter-
acted the consequences of stress on depressive and anxiogenic-like
behavior and on BDNF levels in the hippocampus and frontal cortex
(Ping et al., 2014). Moreover, some case reports describe relief of
depressive symptoms in hypertensive patients treated with the
ACEi captopril (Deicken, 1986; Germain and Chouinard, 1988;
Zubenko and Nixon, 1984).
Despite scarce evidence, it is plausible that drugs acting on the
RAS promote antidepressant-like effects. However, such properties
have not been linked to modulation of the BDNF/TRKB system. In
the present work, we investigated the behavioral effects of the
AGTR1 antagonist losartan and ACEi in a model predictive of
antidepressant-like effect (i.e., forced swimming test) and the
requirement of BDNF/TRKB for such effect. Since AGTR1 activation
is related to brain injury (Saavedra, 2012) and activation of AGTR2
induces neuroprotective outcomes, especially when AGTR1 is
blocked (Mogi and Horiuchi, 2013; Zhao et al., 2005), we hypoth-
esized that activation of AGTR2 mediates the antidepressant-like
effects of losartan. We also performed a series of in vitro analysis
to provide a mechanistic insight to the behavioral data.
2. Material and methods
2.1. Animals
Male Wistar rats (250e350 g) and female C57BL6/j mice
(20e25 g), heterozygous to BDNF expression or WT littermates
were used in behavioral studies. The rats were housed in pairs
while mice were group-housed (4e6/cage) in temperature-
controlled room (24± 1 C), under standard laboratory conditions
with access to food and water ad libitum and a 12-h light/12-h dark
cycle (light on at 6:30 a.m.). In vivo experiments were conducted
with approval of the local Ethical Committee (protocol 147/2017 for
University of S~ao Paulo and ESAVI/10300/04.10.07/2016 for Uni-
versity of Helsinki), which are in accordance with the Brazilian
Council for the Control of Animals under Experiment (CONCEA),and the European Union and ARRIVE guidelines (Kilkenny et al.,
2010) for the care and use of laboratory animals. All licenses
comply with international laws and policies.
2.2. Cell culture
Mouse ﬁbroblasts stably overexpressing full-length TRKB
(MG87.TRKB) were cultured in Dulbecco's Modiﬁed Eagle's Me-
dium (DMEM) (supplemented with 10% fetal calf serum, 1% peni-
cillin/streptomycin,1% L-glutamine, and 400mg/ml G418). Cell lines
weremaintained at 5% CO2 and 37 C until reaching 70% conﬂuence
for experiments. For primary neuronal cultures, cortices from E18
rat embryos were dissected and tissue was dissociated with papain
solution in PBS for 10min at 37 C. Cells were suspended in DMEM
medium containing Ca2þ/Mg2þ-free HBBS, 1mM sodium pyruvate,
10mM HEPES (pH¼ 7.2) and DNAse, and plated onto poly-l-lysine-
coated 24-well or 96-well plates at a cell density of 125 000 cells/
cm2. Primary neurons were maintained in Neurobasal medium
(supplemented with 2% B27, 1% penicillin/streptomycin and 1% L-
glutamine) and supplemented with fresh medium every third day.
2.3. Drug treatments
Losartan potassium (losartan; AGTR1 antagonist; Pharmanostra,
Brazil) was administered intraperitoneally (ip) in rats (10, 30, and
45mg/kg), intracerebrally (0.1, 1, and 10 nmol/site), in cell cultures
(10mM; Tocris #3798, USA) and ip in mice at 45mg/kg. Captopril
(angiotensin converting enzyme inhibitor - ACEi; 3, 10, and 30mg/
kg; Pharmanostra, Brazil) and enalapril (ACEi; 1, 3, and 10mg/kg;
Pharmanostra, Brazil) were injected ip. K252a (TRK antagonist,
Sigma-Aldrich, #K2015, Germany) was used for intracerebral
(20mM/site), or in culture (10mM) treatment. PD123319 (PD; AGTR2
antagonist; Tocris, #1361, USA) was used for intracerebral (200mM/
site) or culture (200 nM) treatment. ANG2 (10mM; Tocris #1158,
USA), BDNF (2.5 ng/ml, Peprotech, USA), NGF (10 ng/mL, Sigma-
Aldrich, Germany), TRKB.Fc (200 ng/ml; R&D systems, #688-TK-
100, USA), and CGP42112 (CGP; AGTR2 agonist; 2uM; Tocris, #2569,
USA) were used only for cell culture treatment. K252a and
PD123319 intracerebral doses were chosen based on previous
studies (Jiang et al., 2012; Zheng et al., 2008). 2.5% 2,2,2 tri-
bromoethanol (ip, Sigma-Aldrich, #T48402) and subcutaneous
local anesthetic lidocaine (PROBEM 3%, 0.2ml) were used for ste-
reotaxic surgery. Chloral hydrate (0.75 g/kg, ip, Sigma-Aldrich,
#C8383, Germany) was used to euthanize animals for perfusion.
Subcutaneous banamine (Schering-Plough, 0.25%, 0.1ml/100 g)
and intramuscular oxytetracycline (Pﬁzer, 20%, 0.1ml/100 g) were
used once for postoperative recovery. Losartan, tribromoethanol,
chloral hydrate, and banamine were freshly prepared in saline so-
lution. All other drugs were prepared in 0.1% DMSO in saline.
2.4. Surgery, intracerebral injections, and histology
Surgery and intracerebral drug injections were performed as
previously described (Diniz et al., 2016). Brieﬂy, rats were anes-
thetized with tribromoethanol and ﬁxed in a stereotaxic frame.
Stainless steel guide cannulas (0.7 mm OD) aimed at the dorsal
hippocampus (dHC; coordinates: AP ¼ 4.0 mm from bregma,
L ¼ 2.8 mm, DV ¼ 2.1 mm), ventral hippocampus (vHC; co-
ordinates: AP ¼ 5.0 mm from bregma, L¼ 5.2 mm, DV¼ 4.0 mm),
or prelimbic ventromedial prefrontal cortex (PL; coordinates:
AP ¼ þ3.3 mm from bregma, L ¼ 1.9 mm, DV ¼ 2.4 mm; lateral
inclination of 22) were implanted according to the atlas of Paxinos
and Watson (1998) and attached to skull bone with stainless steel
screws and acrylic cement. A stylet inside the guide cannula pre-
vented obstruction. Five to seven days after surgery, intracerebral
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volume of 200 nl (mPFC) or 500 nl (dHC or vHC) infused for 1min
using a Hamilton microsyringe (Sigma-Aldrich) and infusion pump
(KD Scientiﬁc) 20min before the test session. After behavioral tests,
rats were anesthetized with chloral hydrate and 200 nl of methy-
lene blue was injected through the guide cannula. The brains were
removed and injection sites veriﬁed. Results from injections
outside the targeted area were discarded from statistical analysis.
All histological sites of injectionwere inserted in diagrams (Figs. S2
and S3) according to the atlas of Paxinos and Watson (1998).
2.5. Forced swimming test
The forced swimming test (FST) was performed on rats as fol-
lows: animals were placed individually to swim in a Plexiglas cyl-
inder (24 cm diameter by 60 cm height with 28 cm of water at
25± 1 C) for 15min (pretest). Twenty-four hours later, animals
were placed again in the cylinder for a 5min swim test session and
immobility time was measured (Diniz et al., 2016).
The FST in mice was performed as follows: the animals were
placed in 5 L glass beaker cylinders (19 cm diameter, with a 20 cm
water column) for 6min. The immobility was assessed in the last
4min of the session (Diniz et al., 2017). For both protocols, water
was changed between each test. After swimming, animals were
towel-dried and kept in a warmed cage before returning to home
cages. The test was videotaped and analyzed by a trained observer
blind to treatment.
2.6. Overexpression of GFP-AGTR2
MG87 cells were transfected to express GFP-tagged AGTR2 using
lipofectamine (Jiang et al., 2012). Brieﬂy, at a conﬂuence of 70%, the
cells were incubated with a mixture of 2.5% lipofectamine 2000
(Thermo Scientiﬁc, #11668019) and 5ug/ml of the plasmid in
OptiMEM medium. Forty-eight hours after transfection, cells were
treated, lysed, and subject to immunoprecipitation as described
below.
2.7. Sample collection
For immunoassays, cells were washed with ice-cold PBS and
lysed (137mM NaCl, 20mM Tris-HCl, 1% NP40, 0.5mM NaF, 10%
glycerol, pH¼ 7.4; supplemented with protease/phosphatase in-
hibitor cocktail [Sigma-Aldrich, #P2714; #P0044] and sodium
orthovanadate [0.05%, Sigma-Aldrich, #S6508]). Samples were then
centrifuged at 10000 g for 15min at 4 C. Supernatant was
collected and stored at 80 C until use. For polymerase chain re-
action, the cells were washed with PBS and treated with Qiazol
Lysis Reagent™ (Qiagen). Lysate was collected in a clean tube and
incubated with chloroform for 3min at room temperature (RT).
After centrifugation at 15200 g for 10min at 4 C, the aqueous
phase was mixed with isopropanol for 10min at RT and centrifuged
at 15200 g for 10min at 4 C. The pellet was washed twice with
75% EtOH, once with 100% EtOH, air-dried, and dissolved in 20ul
MQ water.
2.8. Reverse transcription-polymerase chain reaction and
quantitative polymerase chain reaction
The concentration and purity of each RNA sample were deter-
mined using NanoDrop (Thermo Scientiﬁc). Maxima First Strand
cDNA Synthesis Kit for RT-qPCR with dsDNase (#K1672, Thermo
Scientiﬁc) was used to synthesize cDNA from the samples. Primers
were designed via https://eu.idtdna.com/pages/scitools and pur-
chased from Sigma-Aldrich. The following primers were used forquantitative polymerase chain reaction (qPCR): Agtr1a-
(NM_030985.4) forward: CATCAGTCTCCCTTTGCTATGT; reverse:
AGTGACCTTGATTTCCATCTCTT.
Agtr2-(NM_012494.3) forward: CCTTCCATGTTCTGACCTTCTT;
reverse: GCCAGGTCAATGACTGCTATAA. Actin-(NM_031144)
forward:
TGTCACCAACTGGGACGATA; reverse:
GGGGTGTTGAAGGTCTCAAA.
The PCR method used SYBR Green as probe. Brieﬂy, max-
ima®SYBRGreen qPCRMaster Mix (Thermo Scientiﬁc, #K0253) was
used according to manufacturer's instructions in a Hard-Shell™ 96-
well PCR plate (BioRad). The reaction was conducted in duplicates
using a thermal cycler (BioRad CFX96 Real-Time System) with
initial denaturation at 95 C for 10min. Denaturation and ampliﬁ-
cation were performed in 45 cycles of 95 C for 15s, 63 C for 30s,
and 72 C for 30s. No template control (NTC) was included in the
reaction and melting curve analysis was performed. Results were
analyzed using Ct values. Beta-actin mRNA levels were used for
normalization of the results and 2DDCt values were calculated for
each gene.
2.9. Immunoprecipitation
Lysates from transfected MG87.TRKB/GFP-AGTR2 cells were
incubated with antibody against TRK (Santa Cruz, #sc7268) over-
night (1ug of Ab; 500ug of total proteins) at 4 C. Following incu-
bation with Protein-G Sepharose (Life Technologies, #101242) for
2 h at 4 C, samples were centrifuged at 10000 g for 2min, the
supernatant was stored, and this cycle was repeated twice, using
lysis buffer towash the samples and the supernatant discarded, and
the precipitate was stored at 80 C until use.
2.10. Western blotting and ELISA
For western blotting, protein precipitated by anti-TRK and su-
pernatant were separated in SDS-PAGE and transferred to PVDF
membranes. Following blocking with 3% BSA in TBST, membranes
were incubated with antibody against GFP (1:1000; Santa Cruz,
#sc-8334) or total TRK (1:1000; Santa Cruz, #sc11-Rb). Membranes
were incubated with secondary antibody conjugated to HRP
(1:10000; Bio-Rad, #170e5046) and chemiluminescence emitted
after addition of ECL was detected by a CCD camera. Immunoblot
bands were measured using NIH ImageJ 1.32.
For ELISA, samples (120mg total proteins) were incubated over-
night at 4 C in 96-well plates previously coated with anti-TRK
(1:500; Santa Cruz, #sc7268, overnight at 4 C) and blocked with
3% BSA for 2 h at RT in PBST. Following a wash with PBST, anti-
pTRK.Y816 (1:2000; Cell Signaling, #4168), biotin-conjugated
anti-pY (1:2000; AbD Serotec, UK, #MCA2472B), or anti-FYN
(1:2000; Santa Cruz, #sc16) was incubated overnight at 4 C. Af-
ter awash with PBST, the platewas incubated with HRP-conjugated
tertiary antibody (1:5000; Bio-Rad, #170e5046) or HRP-
conjugated streptavidin (1:10000; Thermo Fisher, #21126).
Chemiluminescence emitted after addition of ECLwas detected by a
plate reader (Varioskan Flash, Thermo-Fisher). The signal from each
sample was subtracted of blank and normalized by the value of
vehicle-treated samples, thus expressed as percentage of the con-
trol group.
2.11. Surface expression of TRK
Cells from rat E18 cortex were cultivated in 96-well plates as
described above (DIV8). Detection of surface TRKB was performed
by ELISA (Zheng et al., 2008). Cells were ﬁxed with 4% PFA for
20min at RT. After washing with PBS, wells were blocked with 5%
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Primary antibody against the extracellular portion of TRK (1:500,
Santa Cruz, #sc8316) was then incubated overnight at 4 C.
Following a wash with PBS, cells were incubated with HRP-
conjugated antibody (1:5000; Bio-Rad, #170e5046) for 2 h at RT.
Signal detected after addition of ECL and subtracted of blank were
normalized by the average of vehicle-treated samples, and
expressed as percentage of the control group.
2.12. Data analysis
Statistical analyses were performed using two-tailed Student's
t-test, one- or two-way analysis of variance (ANOVA) followed by
Fisher's LSD post-hoc test. Criteria for statistical signiﬁcance was
p< 0.05.
3. Results
3.1. Antidepressant-like effect of losartan
Different classes of drugs with diverse mechanisms regarding
RAS modulation were used to evaluate a possible drug-induced
antidepressant effect. As depicted in Fig. 1c, one-way ANOVA in-
dicates a signiﬁcant effect of losartan treatment (F4,46¼ 8.27,
p< 0.05). Both losartan doses (10 and 45mg/kg) and imipramine
(30mg/kg, used as positive control) reduced the immobility time inFig. 1. Antidepressant-like effect of losartan. Animals were treated ip 24, 5, and 1 h
before FST with captopril (a) at 0, 3, 10, or 30 mg/kg (n ¼ 7e9/group) doses or with
enalapril (b) at 0, 1, 3, or 10 mg/kg (n ¼ 5/group) doses. (c) Losartan was administered
ip 1 h before FST at 0, 10, 30, or 45 mg/kg and imipramine at 30 mg/kg was used as
positive control (n ¼ 5e16/group). (def) Losartan was bilaterally infused at 0, 0.1, 1, and
10 nmol/side into (d) dorsal hippocampus (dHC, n ¼ 4e8/group), (e) ventral hippo-
campus (vHC, n ¼ 3e4/group), or (f) prelimbic prefrontal cortex (PL, n ¼ 5e7/group)
20min before the test session. Data are expressed as mean ± SEM of immobility time
(s); *p<0.05 compared with control group.FST (Fisher's LSD p< 0.05 for all). On the other hand, captopril
(F3,29¼1.83, not signiﬁcant: NS) and enalapril (F3,16¼ 0.46, NS)
treatment were not effective in decreasing immobility time in the
FST, as found in Fig.1a and b. The immobility time of rats exposed to
a swimming session is increased after uncontrollable stress and
treatment with antidepressant drugs decreased this parameter
(Nestler and Hyman, 2010). Moreover, provided that known anti-
depressants decrease immobility time in FST, good predictive val-
idity is attributed to this test, thus supporting FSTas a screening test
for putative new antidepressant drugs and their mechanisms. Since
only systemic losartan exhibited an antidepressant-like effect, this
drug was infused into dHC, vHC, or PL to address which of these
structures may mediate such effect. The data shown in Fig. 1def
indicate that losartan infused into vHC (F3,11¼10.66, p< 0.05) and
PL (F3,19¼ 2.72, p< 0.05) but not into dHC (F3,24¼ 0.50, NS), was
able to decrease immobility time in the FST.
3.2. Interaction between losartan and TRK or AGTR2: in vivo data
The requirement for TRK or AGTR2 activation (or both) for the
antidepressant effect of losartanwas examined. As shown in Fig. 2a
and b, K252a (a TRK receptor antagonist) infused into vHC or PL was
able to modulate the effect of systemically injected losartan. Two-
way ANOVA revealed an interaction between factors (systemic
and intracerebral injection) for both structures (vHC: F1,15¼ 8.62;
PL: F1,13¼ 6.58; p< 0.05 for both). For vHC experiments, pairwise
comparisons indicated that the immobility time of losartan/ctrl
group is decreased compared with the ctrl/ctrl group (Fisher's LSD,
p< 0.05). The losartan/K252a groupwas signiﬁcantly different than
the losartan/ctrl group (Fisher's LSD, p< 0.05), suggesting that
K252a prevents the antidepressant-like effect of losartan. For PL
experiments, pairwise comparisons revealed that the immobility
time of animals treated with losartan/ctrl is lower than that of the
control group (Fisher's LSD, p< 0.05). The losartan/K252a group
was different compared to the losartan/ctrl group (Fisher's LSD,
p< 0.05), suggesting that K252a also prevents losartan effect in this
brain region.
We next analyzed if the antidepressant effect of losartan relies
on AGTR2 activity. As shown in Fig. 2c and d, the AGTR2 antagonist
PD123319 infused into PL, but not into vHC, was able to mitigate the
effect of systemically injected losartan. Accordingly, two-way
ANOVA revealed interactions between the compounds in PL
(F1,28¼ 5.11, p<0.05) but not in vHC (F1,26¼ 0.18, NS). In addition,
pairwise comparisons concerning PL experiments indicated that
the immobility time of losartan/ctrl group is reduced compared
with the ctrl/ctrl group (Fisher's LSD, p<0.05). However, the los-
artan/PD123319 groupwas not different from losartan/ctrl (Fisher's
LSD: t28¼ 1.95, p¼ 0.06). Therefore, activation of AGTR2 in PL, but
not in vHC, is necessary to mediate the antidepressant-like effect of
losartan.
Finally, we submitted BDNF haploinsufﬁcient mice and their
littermate (WT) controls to FST. As shown in Fig. 2e, the adminis-
tration of losartan decreased the immobility time only in WT ani-
mals, while no effect was observed in animals with reduced BDNF
levels (interaction: F1,24¼10.15; p<0.05). Considering only the WT
group, one-way ANOVA indicated that both losartan (45mg/kg)
and ﬂuoxetine (30mg/kg; used as a positive control) reduced
immobility in the FST [mean immobility time in seconds/SEM/n,
ctrl¼ 150.6/8.3/7, losartan¼ 64.25/15.40/8, ﬂuoxetine¼ 39.8/9.65/
5; F2,17¼ 20.44; p<0.05; data not shown].
3.3. Interaction between TRK and AGTR2: in vitro data
Since the losartan antidepressant-like effect may depend
mutually on TRKB and AGTR2 signaling in PL, we hypothesized that
Fig. 2. In vivo data on interaction between losartan and TRK or AGTR2. The antidepressant-like effect of losartan was attenuated by K252a infused into (a) PL (n ¼ 4e5/group) and
(b) vHC (n ¼ 4e6/group). The infusion of the AGTR2 antagonist PD123319 into (c) PL (n ¼ 7e9/group) attenuated the effect of systemically injected losartan, but no change was
observed in (d) vHC (n ¼ 4e6/group). (e) Interaction between genotype and losartan effect in mice haploinsufﬁcient to BDNF or WT littermates (n ¼ 5e8/group). Losartan was
administered 1 h before FST and either K252a or PD123319 was bilaterally infused 20 min before the test session. Data are expressed as mean ± SEM of immobility time (s). *p<0.05
compared with ctrl/ctrl group, unless otherwise stated; #p<0.05 compared with PD/VEH group. @P¼ 0.06 compared with PD/VEH group.
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to forward TRKB activation. To test this possibility, losartan,
PD123319, or K252a (ﬁrst factors) was added to the primary cell
cultures 10min prior to ANG2 (second factor) and pTRK levels were
analyzed 10min after the last administration. Two-way ANOVA
indicated an interaction between both factors (F3,28¼ 6.77, p<0.05)
and pairwise comparisons revealed that both PD123319 and K252a
prevented the ANG2 effect of increasing pTRK levels (Fisher's LSD,
NS for both; Fig. 3a); no additive effect was observed with the
combination of ANG2 and losartan. We next determined if the
ANG2 effect was dependent on BDNF release. To test this possibility,
a soluble BDNF scavenger (TRKB.Fc, ﬁrst factor) was added to the
cell culture medium 10min before ANG2 (second factor). Two-way
ANOVA did not indicate an interaction between both factors
(F1,20¼ 0.82, NS), suggesting that the effect of ANG2 on pTRK levels
does not involve increment on BDNF release (Fig. 3b).
Next, PD123319 (ﬁrst factor) was added to the culture medium
10min before BDNF (second factor) and pTRK levels were analyzed.
Two-way ANOVA showed a signiﬁcant interaction between factors
(F1,20¼ 36.18, p<0.05). Pairwise comparisons indicated that
PD123319 abrogated the BDNF effect of increasing pTRK levelsFig. 3. In vitro data on interaction between TRK and AGTR2. (a) Prior administration of PD
cortical cells of rat embryo (E18 cortex cells; DIV8-10, n ¼ 4e6/group). (b) Previous incubat
cells (n ¼ 6/group). Previous incubation with PD123319 blocked (c) BDNF-induced and (e)
tagonists or TRKB.Fc were administered 10min before ANG2, BDNF or NGF. *p<0.05 compa(Fisher's LSD, p<0.05; Fig. 3c), suggesting that AGTR2 participates in
BDNF-induced TRK activation. In addition, prior administration of
PD123319 (ﬁrst factor) was not able to prevent the NGF (second
factor) effect of increasing pTRK levels (Fig. 3d), since no interaction
between both factors was observed (F1,13¼ 0.60, NS). Administra-
tion of the AGTR2 agonist CGP42112 was also able to increase pTRK
levels, and such effect was blocked by prior administration of
PD123319 (interaction, F1,20¼ 9.78; p<0.05; Fig. 3e).3.4. AGTR2-dependent interaction with FYN, surface positioning of
TRKB, and co-immunoprecipitation of AGTR2 and TRKB
Next, we decided to verify if ANG2 acting on AGTR2 is able to
inﬂuence TRK/FYN coupling, given that FYN is a SRC member
responsible for transactivation of TRK (Rajagopal and Chao, 2006).
To test this, PD123319 (ﬁrst factor) was added to the culture me-
dium 10min before ANG2 or BDNF (second factors) and TRK/FYN
coupling was analyzed. Interestingly, two-way ANOVA indicated a
signiﬁcant interaction between ANG2 and PD123319 (F1,19¼ 5.08,
p< 0.05) and, surprisingly, between BDNF and PD123319
(F1,20¼ 6.74, p<0.05). Pairwise comparisons showed that PD123319or K252a, but not losartan, blocked the ANG2-induced increase in TRKB activation in
ion with TRKB.Fc did not change ANG2-induced increase in TRKB activation in cortical
CGP42112-induced, but not (d) NGF-induced activation of TRK (n ¼ 4e6/group). An-
red with ctrl/ctrl group; cells were lysed 10min after last drug administration.
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coupling (Fisher's LSD, NS for both; Fig. 4a). Next, we determined if
PD123319 or ANG2 modulates surface levels of TRKB. Cultured
cortical cells exposed to PD123319 had decreased surface levels of
TRKB; the converse was observed with ANG2 increased
(F2,30¼ 24.33; Fig. 4c).
Altogether, these results point to the existence of a heterodimer
TRKB/AGTR2, since previous studies have described cross-
antagonism (ability of both antagonists of each receptor unit in
the heterodimer to block signaling of the other's agonist) as a
ﬁngerprint of heterodimerization (Ellis et al., 2006; Ferrada et al.,
2009). Consistent with this idea, GFP-tagged AGTR2 co-
precipitated with TRKB (Fig. 4d).3.5. Incubation with glutamate inverts the ratio between AGTRs in
cortical cells
A preliminary comparison between the presented in vitro and
in vivo analysis indicated an incompatibility regarding the effects of
losartan. This compound, although effective when injected sys-
temically or into mPFC, did not exert any effect per se in cultured
cortical cells. Therefore, we considered the putative role of pretest
stress in animals. In this scenario, a single exposure to inescapable
stress, in addition to a peak in corticosterone production (lasting for
2 h), increases glutamate levels for up to 24 h (Musazzi et al., 2016;
Popoli et al., 2011). Therefore, we ﬁrst determined the levels of
Agtr1a and Agtr2 mRNA in our cultured cells. As shown in Fig. 5a,
we observed a 5-fold higher expression of Agtr2 than that of Agtr1a
(Mean DCt value/SEM/n; Agtr1a, 17.08/0.09/3; Agtr2, 14.69/0.37/3;
t4¼ 2.96, P<0.05). Further, we incubated cortical cells with gluta-
mate (10 or 100uM/2 h) and determined the levels of agtrmRNA. A
separate analysis of agtr expression following glutamate suggested
a decrease in Agtr2 mRNA levels (mean of fold change/SEM/n from
ctrl¼ 1.00/0.09/5; glutamate 10uM¼ 0.88/0.06/5; glutamate
100uM¼ 0.47/0.10/4) but no change in Agtr1a (fold change from
ctrl¼ 1.00/0.10/5; glutamate 10uM¼ 1.39/0.14/5; glutamate
100uM¼ 1.12/0.11/4). Under this condition, there was an inversion
in the ratio between Agtr1a and Agtr2 mRNA levels (glutamate
10uM¼ 1.5-fold more Agtr1a; glutamate 100uM¼ 2.54-fold more
Agtr1a; Fig. 5b). Cortical cells pre-exposed to glutamate (100mM/
2 h) were then tested 24 h later for the interaction between losartan
and ANG2. Interestingly, 24 h after incubation with glutamate
(putatively inverting the Agtr1a/Agtr2 ratio), losartanwas necessary
for the effect of ANG2 on pTRK levels (interaction: F1,20¼14.46,
p<0.05; Fig. 5c).Fig. 4. AGTR2-dependent interaction with FYN, surface positioning of TRKB, and co-immun
coupling induced by (a) ANG2 (n ¼ 5e6/group) or by (b) BDNF (n ¼ 6/group). (c) PD123319
cells (n ¼ 9e12/group). (d) Sample from MG87.TRKB ﬁbroblast cell line, overexpressing AGT
compared with ctrl/ctrl group, unless otherwise stated; cells were lysed 10min after last d4. Discussion
The present study indicates that systemic treatment with
angiotensin receptor blocker (ARB) losartan and imipramine (used
as positive control), but not with the ACE inhibitors captopril or
enalapril, promoted an antidepressant-like effect in the FST. Los-
artan infusion into vHC or into PL, but not into dHC, was sufﬁcient
to mimic the antidepressant-like effect of systemic injection. Both
the hippocampus and vmPFC are core structures that modulate
motivational and emotional behavioral consequences of stress
exposure, including depressive disorders (Castren, 2005; Nestler
et al., 2002). Consistent with our data, vHC is suggested to be
mainly related to behavioral and physiological consequences of
stress exposure, while dHC engages cognitive and learning pro-
cesses concerning spatial navigation (Fanselow and Dong, 2010).
The antidepressant-like effect of losartan probably relies on TRK
signaling acting in the hippocampus and vmPFC prelimbic aspects,
whereas AGTR2 activation is required only in PL, since an inhibitor
of TRK in vHC and PL, and an AGTR2 antagonist in PL decreased such
effect. Moreover, we can rule out any nonspeciﬁc effect on loco-
motion, a common misleading factor in FST, since no change was
observed in this parameter following the pharmacological treat-
ments (Fig. S1). The differences between these two structures can
be explained by the higher levels of AGTR2 found in medial aspects
of prefrontal cortex than in hippocampus. The study from De Kloet
and colleagues (de Kloet et al., 2016), using GFP expression to report
for AGTR2 expression, demonstrated positive labelling for the
ﬂuorescent protein in the medial prefrontal cortex of mice. The
same study found very low levels of GFP in the hippocampus of
these animals. In line with this observation, the levels of Agtr2 in
mouse hippocampus are found below the cutoff used in Gregg and
cols. study (Gregg et al., 2010). However, using a functional
approach it was observed that ANG2 amnesic effect is counteracted
by the AGTR2 antagonist PD123319 in the hippocampus (Kerr et al.,
2005).
The sequential behavioral approach used in the present study
reinforced the involvement of the BDNF/TRKB system in the effect
of losartan. In mice with dampened BDNF expression, losartan was
no longer able to exert antidepressant-like effects. Similar to what
was observed after losartan treatment, these mice are not
responsive to classical antidepressants, such as imipramine and
ﬂuoxetine (Castren and Antila, 2017; Karpova et al., 2011;
Saarelainen et al., 2003).
To corroborate the behavioral experiments and to further
explore the mechanisms involved in losartan effects, we usedoprecipitation of AGTR2 and TRKB. Prior treatment with PD123319 impaired TRK:FYN
decreased while ANG2 increased the levels of TRKB on the surface of cultured cortical
R2 labeling on blotting membrane from immunoprecipitation of TRKB protein. *p<0.05
rug administration.
Fig. 5. (a) Agtr2 subtype has a 5-fold higher mRNA expression than Agtr1a (n ¼ 3/group). (b) Incubation with glutamate (10 or 100 mM/2 h) inverts this ratio in favor of AGTR1. (c)
Cells challenged with glutamate (100 mM/2 h) and tested for ANG2-induced activation of TRKB 24 h later were responsive only in the presence of losartan (n ¼ 6/group). *p<0.05
from ctrl or Agtr1a group. (d) Graphical abstract for the TRKB-dependent antidepressant-like effect of losartan. In vivo basal conditions, the high levels of AGTR1 compared with
AGTR2 in prefrontal cortex would be responsible to maintain TRKB out of the cell surface. Upon blockade of AGTR1, the activation of AGTR2 increases surface levels of TRKB and
favors its docking to FYN.
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between RAS and BDNF/TRKB signaling. First, we observed that
K252a and PD123319, but not losartan, prevented the ANG2 effect
of increasing pTRK levels, thus suggesting a putative action on
AGTR2. This possibility is strengthened by the administration of
AGTR2 agonist CGP42112, that also induced an increase in TRK
activation, and this effect was counterbalanced by prior incubation
with the AGTR2 antagonist PD123319. Since the soluble form of
TRKB (TRKB.Fc) did not prevent the ANG2 effect on pTRK, it is
plausible to consider that AGTR2-induced activation of TRKB would
not require increment in BDNF release. In this sense, transactivation
of TRKB or a facilitatory effect of basal levels of BDNF on its receptor
are reasonable scenarios. Previous studies have described that both
the GPCR ligands adenosine and pituitary adenylate cyclase-
activating polypeptide can transactivate TRK (Rajagopal et al.,
2004). In addition, TRK transactivation by an adenosine 2A recep-
tor agonist was blocked by PP1, suggesting involvement of the SRC
family tyrosine kinase (Lee and Chao, 2001). Thus, FYN and other
SRC-family kinases are responsible for TRK transactivation (Huang
and McNamara, 2010; Rajagopal and Chao, 2006), and lipid raft
localization of TRKB is regulated by FYN (Pereira and Chao, 2007).
Consistent with this evidence, we observed that ANG2 was also
able to increase levels of TRK/FYN coupling in cortical cultures.
Therefore, we propose that FYN acts as an intermediary molecule
capable of inducing TRKB transactivation when ANG2 acts on
AGTR2. Moreover, BDNF itself promotes TRKB/FYN coupling
(Iwasaki et al., 1998). Corroborating that prospect, our data alsoshowed that BDNF increased TRKB/FYN coupling. Therefore, both
ANG2 and BDNF, which are able to increase pTRK levels, also induce
TRK/FYN coupling.
As expected, PD123319 blocked TRKB/FYN coupling from ANG2
action, but unexpectedly PD123319 also prevented such coupling
from BDNF action. Also unexpected was the data indicating that
PD123319 prevents the BDNF effect of increasing pTRKB levels. A
generalized interaction of AGTR2 with other TRK members is un-
likely, as PD123319 did not prevent NFG action of increasing pTRKA
levels. These unforeseen interactions can be explained by the
observation that PD123319was able to reduce surface expression of
TRKB, whereas ANG2 led to an increase, thereby suggesting a pu-
tative displacement of TRK to the surface upon AGTR2 signaling and
a decrease of BDNF effectiveness with prior PD123319. Indeed,
modulation of TRK surface trafﬁcking is important considering the
two possible scenarios mentioned above for the activation of TRKB,
which may occur on cell membrane (Rajagopal et al., 2004). In
addition, the MG87.TRKB cell line, which overexpresses TRKB,
allowed us to observe co-immunoprecipitation of GFP-tagged
AGTR2 and TRKB, suggesting AGTR2/TRKB dimerization. This
approach was chosen for the following two reasons: ﬁrst, as
analyzed by the group of Juan Saavedra, commercially available
antibodies against AGTRs are far from ideal (Hafko et al., 2013); and
second, the cell line used expresses exclusively TRKB, thus being an
ideal tool for our purpose.
A preliminary analysis showed that Agtr2 mRNA levels were 5-
fold higher than Agtr1a in our primary cultures, and this ratio
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mate. This later feature seems to allow a cooperative effect of los-
artan and ANG2. Using a model of retinal ischemia, it was observed
that increased expression of Agtr1a mRNA peaked 12 h after
reperfusion, while treatment with candesartan was able to prevent
ischemia-induced glutamate release (Fujita et al., 2012). Taken
together, these data indicate a possible positive feedback between
AGTR1 signaling and glutamatergic transmission. Moreover,
consistent with our in vitro observations, Agtr1a levels increased
while Agtr2 levels decreased in the medulla of stress-induced hy-
pertensive rats (Du et al., 2013). However, an opposite effect of
glutamate on Agtr2 mRNA has also been described (Makino et al.,
1998). In this study, glutamate insult led to an increase of Agtr2
mRNA. The precise mechanism where glutamate release might
reduce the levels of Agtr2 are still not understood and these
apparent discrepancies could rest on methodological differences.
For example, the culture method of Makino and colleagues rely on
cortical cells cultivated for 14 days, supplemented with calf serum
and mitosis inhibitors; our cultures were serum-free (substituted
by B27) and cultivated for 8 days without any drugs to prevent cell
proliferation.
Given that the FST protocol for mice does not engage the
exposure to a previous stressful session, posits that Agtr1a levels
could be kept higher by basal glutamatergic transmission rather
than by stressful stimuli as postulated before. To address this pos-
sibility, we used the EMBL-EBI Expression Atlas (https://www.ebi.
ac.uk/gxa/home) to compare the expression of Agtr1a and Agtr2
in the murine brain. We only obtained data from RNAseq experi-
ments conducted in four strains of mice by Gregg and colleagues
(Gregg et al., 2010). Consistent with the proposed scenario, these
authors observed that Agtr2 levels were lower or at least equivalent
to Agtr1a in the medial prefrontal cortex of adult mice. Our
behavioral data, indicating the effectiveness of losartan in mice
submitted to FST, also suggests that the Agtr1a/2 ratio in vivo favors
Agtr1a, since no previous stressful event is presented in this
protocol.
The data obtained from mouse FST, indicating that animals
lacking one copy of BDNF gene do not respond to losartan, is also
apparently contradicting the in vitro lack of interaction between
TRKB.Fc and ANG2. However, the differences between the systems
used can be crucial to the observed responses. As mentioned, in
adult prefrontal cortex, the levels of Agtr1a are higher than Agtr2,
while we observed the opposite in the cultivated cells. Another
source of variation relies on the fact that cultivated cells are not part
of an intrincated, ﬁne-tuned network, therefore submitted to less
inﬂuence of the neighboring cells or structures. Supporting our
in vivo ﬁndings, the decrease of BDNF levels in rats through the
injection of shRNA, blocked the neuroprotective effects of cande-
sartan in a model of stroke (Fouda et al., 2017).
The activation of AGTR1 increases BDNF expression, as found in
human and rat adrenocortical cells (Szekeres et al., 2010), an effect
shared by AGTR2 (Alhusban et al., 2013; Namsolleck et al., 2013),
and associated to the improvement in cognitive performance after
telmisartan (Kishi et al., 2012). Thus, in a speculative scenario, there
is a positive feedback on BDNF production by both receptors.
However, the AGTR2/TRKB heterodimer is positioned in the
membrane; given that the majority of TRKB is internalized
(Haapasalo et al., 2002); where it can be activated by BDNF. Such
effect of BDNF would then be enhanced by the recruitment of FYN
or other SRC-family kinases by the activation of AGTR2.
In conclusion, our ﬁndings indicate that losartan induces an
antidepressant-like effect possibly mediated by AGTR2 and TRKB
coupling in the mPFC. We observed a previously unknown TRKB
activation by AGTR2, involving recruitment of the SRC family kinase
FYN. Our results suggest that TRKB/AGTR2 heterodimer docks theFYN kinase to promote a crosstalk that putatively induces pTRKB/
PLCg1 signaling. However, the higher levels of AGTR1 in the pre-
frontal cortex prevents the ANG2-triggered docking of FYN to the
AGTR2/TRKB complex. Losartan, by blocking AGTR1, facilitates the
AGTR2-mediated effects of ANG2 on TRKB. Considering the high
comorbidity between depression and cardiovascular disorders, our
results suggest that ARBs, such as losartan, could be a therapeuti-
cally viable option in these cases or they could even be a putative
novel class of antidepressant drugs. Still, the present and other
studies allow us to conclude that the relationship between RAS and
BDNF/TRKB systems are far from straightforward, and further
studies are necessary, taking into account the limitations of each
approach used.
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